Experts in endocrinology review the updated ADA diabetes-management guidelines and highlight the inclusion of CGMs and the indications surrounding their use.
Elena A. Christofides, MD, FACE, and David T. Ahn, MD, discuss the inherent challenges associated with blood glucose monitoring in patients with type 1 and 2 diabetes.
The American Academy of Neurology recently issued a guideline on oral and topical treatments for painful diabetic neuropathy. Here, a concise summary for clinicians.
Use of continuous glucose monitoring to assess time in target glucose range in T2D patients was evaluated in a systematic literature review covering ~14 000 participants.
WATCH: The FDA approval of semaglutide 2.4 mg for adults with obesity was "by far the big event in 2021," said Donna Ryan, MD. More from our look back/look ahead interview, here.
The ADA's annual update to its comprehensive evidence-based standards includes new guidance on diabetes screening, first-line therapies, and comorbid NAFLD/NASH.
CGMs have revolutionized diabetes management for patients and healthcare providers alike. This slide show summarizes the most recent enhancements.
Continuous glucose monitoring for type 2 diabetes patients is gaining exposure in the literature with positive evidence accumulating. Examples follow.
While use of insulin pumps and CGM increased over a 3-year study period for all racial-ethnic groups, the inequities were significant between White adults and all others.
Increases in obesity parameters significantly increased risk of incident heart failure in persons with diabetes, but not without diabetes, in a large community-based cohort study.